Premium
Matrix‐metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma
Author(s) -
Lein Michael,
Jung Klaus,
Laube Christian,
Hübner Tobias,
Winkelmann Bjoern,
Stephan Carsten,
Hauptmann Steffen,
Rudolph Birgit,
Schnorr Dietmar,
Loening Stefan A.
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(20000315)85:6<801::aid-ijc11>3.0.co;2-c
Subject(s) - matrix metalloproteinase , renal cell carcinoma , pathology , kidney , medicine , carcinoma , cancer
Matrix‐metalloproteinases (MMPs) are associated with invasive and metastatic behavior of several human malignant tumors. We have determined MMP‐2 and MMP‐9 and tissue inhibitors of MMPs (TIMP‐1 and TIMP‐2) in blood plasma and in renal tissue samples of patients with renal cell carcinoma (RCC) from cancerous and non‐cancerous parts of the same kidney. In tumor tissue, MMP‐9 and TIMP‐1 were significantly higher than in normal counterparts. MMP‐2 was not different between tumor tissue and normal counterparts. TIMP‐2 values could not be measured. In plasma, MMP‐9 concentrations were significantly higher in RCC patients than in healthy controls, MMP‐2 and TIMP‐2 concentrations were higher in healthy controls and TIMP‐1 concentrations were not different. Int. J. Cancer 85:801–804, 2000. © 2000 Wiley‐Liss, Inc.